文献速递甲状腺疾病

[18F]-FDG-PET/CT与仑伐替尼治疗放射性碘难治性甲状腺癌的疗效及生存相关

[18F]-FDG-PET/CT Correlates With the Response of Radiorefractory Thyroid Cancer to Lenvatinib and Patient Survival.
PubMed 文献 · J Clin Endocrinol Metab · 2021-01-01

研究纳入33例进展期放射性碘难治性分化型甲状腺癌(RAI-R DTC)患者,在仑伐替尼治疗前及随访中行生化、形态学(全身CT)和代谢([18F]-FDG-PET/CT)评估。结果显示,治疗4周后首次[18F]-FDG-PET/CT的代谢反应可早期预测疗效,并与总生存期相关。

要点

  • 仑伐替尼治疗后4周行[18F]-FDG-PET/CT可早期评估代谢反应
  • 末次[18F]-FDG-PET/CT有代谢反应者中位OS为40.00个月,无反应者8.98个月
  • 末次CT有形态学反应者中位OS为37.22个月,无反应者9.53个月

核心结论

  • [18F]-FDG-PET/CT可早期预测RAI-R DTC患者对仑伐替尼的疗效反应,并与总生存期相关。

研究设计与样本

  • 研究纳入33例接受仑伐替尼治疗的进展期转移性RAI-R DTC患者,在基线及随访中行生化(甲状腺球蛋白及甲状腺球蛋白抗体)、形态学(全身CT)和代谢([18F]-FDG-PET/CT)评估。

主要发现

  • 66.7%的患者在首次[18F]-FDG-PET/CT有代谢反应且首次CT扫描有形态学反应。
  • 治疗4周后[18F]-FDG-PET/CT代谢反应与同期生化反应在60.6%的患者中相关。
  • 末次[18F]-FDG-PET/CT有代谢反应者中位OS为40.00个月,无反应者为8.98个月;末次CT有形态学反应者中位OS为37.22个月,无反应者为9.53个月。
  • 治疗4周后[18F]-FDG-PET/CT有代谢反应者中位OS为36.53个月,无反应者为11.28个月。

关键数值与推荐

  • 末次[18F]-FDG-PET/CT有代谢反应者中位OS为40.00 vs 8.98个月(无反应者)。
  • 末次CT有形态学反应者中位OS为37.22 vs 9.53个月(无反应者)。
  • 治疗4周后[18F]-FDG-PET/CT有代谢反应者中位OS为36.53 vs 11.28个月(无反应者)。

临床怎么用

  • 对接受仑伐替尼治疗的RAI-R DTC患者,可考虑在治疗4周后行[18F]-FDG-PET/CT早期评估代谢反应,辅助预测疗效与生存结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: 18F-fluoro-2-deoxy-D-glucose positron emission tomography-computed tomography ([18F]-FDG-PET/CT)-positive metastatic lesions in radioiodine-refractory differentiated thyroid cancer (RAI-R DTC) have a poor prognosis and lenvatinib represents the best therapy. OBJECTIVE: We investigated the role of [18F]-FDG-PET/CT in the evaluation of metabolic response and prediction of the outcome of RAI-R DTC patients treated with lenvatinib. METHODS: Patients (n = 33) with progressive metastatic RAI-R DTC who were treated with lenvatinib were investigated at baseline and during follow-up with biochemical (thyroglobulin and thyroglobulin antibodies), morphological (whole-body CT scan) and metabolic ([18F]-FDG-PET/CT) evaluation. RESULTS: Nineteen (57.6%) patients showed the greatest metabolic response at the first [18F]-FDG-PET/CT scan, performed after 4 weeks of lenvatinib, while 5/33 (15.1%) patients had this response later. Moreover, 66.7% of patients had both a metabolic response at the first [18F]-FDG-PET/CT scan and a morphological response at the first CT scan. We observed a correlation between the metabolic response at [18F]-FDG-PET/CT scan performed after 4 weeks of treatment and the biochemical response at the same time in 60.6% of patients. The median overall survival (OS) was significantly longer in patients with either a metabolic response at last [18F]-FDG-PET/CT (40.00 vs 8.98 months) or a morphological response at last CT scan (37.22 vs 9.53 months) than in those without response. Moreover, the OS was longer in patients with a metabolic response at [18F]-FDG-PET/CT performed after 4 weeks of treatment (36.53 vs 11.28 months). CONCLUSIONS: Our data show that [18F]-FDG-PET/CT can early predict the response to lenvatinib and correlates with the OS of RAI-R DTC patients treated with this drug.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Valerio L, Guidoccio F, Giani C, et al. [18F]-FDG-PET/CT Correlates With the Response of Radiorefractory Thyroid Cancer to Lenvatinib and Patient Survival. J Clin Endocrinol Metab. 2021. PMID: 33901285. doi:10.1210/clinem/dgab278

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。